Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction

Journal of Cardiac Failure

Volumn 10, Issue 4, 2004, Pages 328-333

  Squire, Iain B ^a,b   Evans, Jon ^c   Ng, Leong L ^a   Loftus, Ian M ^c   Thompson, Matt M ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c NONE

Author keywords

Acute myocardial infarction; BNP; Matrix metalloproteinases

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE WALL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; STATISTICS; STROKE VOLUME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4143147494     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2003.11.003     Document Type: Article

References (25)

1. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., Wild C.J. Left ventricular end systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51
2. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 309:1983;331-336
3. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:1999;3063-3070
4. Spinale F.G., Coker M.L., Krombach S.R., Mukherjee R., Hallak H., Houck W.V., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 85:1999;364-376
5. Wills A., Thompson M.M., Crowther M., Sayers R.D., Bell P.R. Pathogenesis of abdominal aortic aneurysms-cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg. 12:1996;391-400
6. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 31:2000;40-47
7. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 106:2000;55-62
8. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 105:2002;753-758
9. Wang W., Schulze C., Suarez-Pinzon W.L., Dyck J.R.B., Sawicki G., Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischaemia and reperfusion injury. Circulation. 106:2002;1543-1549
10. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variations of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 107:2003;1579-1585
11. Talwar S., Squire I.B., Downie P.F., McCullough A.M., Campton M.C., Davies J.E., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J. 21:2000;1514-1521
12. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929
13. Nagaya N., Goto Y., Nishikimi T., Uematsu M., Miyao Y., Kobayashi Y., et al. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci. 96:1999;129-136
14. Berning J., Steensgaard-Hansen F. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol. 65:1990;567-576
15. Hughes D., Talwar S., Squire I.B., Davies J.E., Ng L.L. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci. 96:1999;373-380
16. Peterson J.T., Li H., Dillon L., Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 46:2000;307-315
17. Romanic A.M., Burns-Kurtis C.L., Gout B., Berrebi-Bertrand I., Ohlstein E.H. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci. 68:2001;799-814
18. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevent cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 10:1999;1135-1142
19. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 32:1998;368-372
20. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 141:2001;211-217
21. Hirohata S., Kusachi S., Murakami M., Murakami T., Sano I., Watanabe T., et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart. 78:1997;278-284
22. Hayashidani S., Tsutsui H., Ikeuchi M., Shiomi T., Matsusaka H., Kubota T., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol. 285:2003;H1229-H1235
23. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 101:2000;1833-1839
24. Wilson E.M., Moainie S.L., Baskin J.M., Lowry A.S., Guy T.S., St John Sutton M., et al. Region and species specific induction of matrix metalloproteinases occurs with post myocardial infarction remodeling. [abstract] Circulation. 106:(Suppl II):2002;. II-345
25. Deschamps A.M., Yarbrough W.M., Sample J.A., McLean J.E., Mingoia J.T., Dowdy K.B., et al. Persistent and selective activation of matrix metalloproteinases within the myocardial interstitial space following ischaemia-reperfusion. [abstract] Circulation. 106:(Suppl II):2002;. II-193